Advertisement
Skip to Content

Biomarin Pharmaceutical Inc BMRN Stock Quote

| Rating as of

NASDAQ: BMRN

Last close prices updated as of Feb 06, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 112.18
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Mid Blend
  • Day Range 110.78  –  112.98
  • Year Range 70.73  –  117.77
  • Market Cap 20.8485 Bil
  • Volume / Avg 902,512.0 /  1.5 Mil
  • Price / Sales 10.62
  • Price / Book 4.56
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis BMRN

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

BioMarin's Rare Disease Portfolio Continues to Support a Narrow Moat

Karen Andersen Sector Strategist

Business Strategy and Outlook

| Karen Andersen |

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development expenses have kept BioMarin in the red, but we're confident in the profit-generating power of its rare-disease treatments, and BioMarin's turn to profitability looks maintainable. With a deep in-house pipeline and the ability to supplement growth with strategic acquisitions, BioMarin is in a strong position.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BMRN

Company Profile BMRN

Business Description

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.

Contact
770 Lindaro Street
San Rafael, CA, 94901
Industry Biotechnology
Employees 3,045

Related Articles BMRN

FAQs for Biomarin Pharmaceutical Inc Stock

No. BMRN does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

BMRN’s market cap is 20.85 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

BMRN’s stock style is Mid Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

BMRN’s price/sales is 10.62.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

BMRN’s price/forward earnings is 32.36.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

BMRN’s price/book is 4.56.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See BMRN’s valuation ratios compared to the Market Index.

BMRN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare BMRN’s historical performance against its industry peers and the overall market.